- Marsden PK. Principles and methods. In: Barrington SF, Maisey MN, Wahl RL, eds. Atlas of Clinical Positron Emission Tomography. 2nd ed. London: Hodder Arnold, 2006: 3–30.
- Blokland AJAK, Pauwels EKJ, Stokkel MPM. The clinical value of 18F-FDG detection with a dual-head coincidence camera: a review. Eur J Nucl Med 2001; 28: 763–778.
- Warburg O. On the origin of cancer cells. Science 1956; 235: 1492–1495.
- Gallagher B, Fowler J, Gutterson N, MacGregor R, Wan C, Wolf A. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19: 1154–1161.
- Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumours: role of positron emission tomography. Endocrine Reviews 2004; 25: 568–580.
- Eriksson B, Örlefors H, Öberg K, Sundin A, Bergström M, Långström B. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab 2005; 19: 311–324.
- Adler LP, Bloom AD. Positron emission tomography of thyroid masses. Thyroid 1993; 3: 195–200.
- Uematsu H, Sadato N, Ohtsubo T et al., Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumours. J Nucl Med 1998; 39: 453–459.
- Van den Bruel A, Maes A, De Potter T et al., Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomographyincidentaloma. J Clin Endocrinol Metab 2002; 87: 1517–1520.
- Grunwald F, Kalicke T, Feine U et al., Flourine-18-flourodeoxy-glucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999; 26: 1547–1552.
- Feine U, Lietzenmayer R, Hanke JP et al., Flourine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37: 1468–1472.
- Wang W, Larson SM, Fazzari M et al., Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000; 85: 1107–1113.
- Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ. PET-FDG of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med 2000; 7: 1010–1015.
- Schluetter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001; 42: 71–76.
- Laking GR, Price PM. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 2002; 12: 1728–1729.
- Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000; 27: 490–496.
- Szakall Jr S, Esik O, Bajzik G et al., 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002; 43: 66–71.
- Melon P, Luxen A, Hamior E, Meurisse M. Fluorine-18-fluorodeoxyglucose positron emission tomography for preoperative parathyroid imaging in primary hyperparathyroidism. Eur J Nucl Med 1995; 22: 556–558.
- Cook GJR, Wong JCH, Smellie WJB, Young AE, Maisey MN, Fogelman I. [11C]Methionine positron emission tomography for patients with persistant or recurrent hyperparathyroidism after surgery. Eur J Endocrinol 1998; 139: 195–197.
- Beggs AD, Hain SF. Localization of parathyroid adenomas using 11C-methionine positron emission tomography. Nucl Med Comm 2005; 26: 133–136.
- Arslan N, Rydzefski B. Detection of a recurrent parathyroid carcinoma with FDG positron emission tomography. Clin Nucl Med 2002; 27: 221–222.
- Erasmus JJ, Patz EF, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997; 168: 1357–1360.
- Boland GW, Goldberg MA, Lee MJ, et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 194: 131–134.
- Maurea S, Mainolfi C, Bazzicalupo L, et al. Imaging of adrenal tumours using FDG PET: comparison of benign and malignant lesions. AJR Am J Roentgenol 1999; 173: 25–29.
- Becherer A, Vierhapper H, Potzi C, et al. FDG-PET in adrenocortical carcinoma. Cancer Biother Radiopharm 2001; 16: 289–295.
- Khan TS, Sundin A, Juhlin C, Langstrom B, Bergstrom M, Erikson B. 11C-Metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging 2003; 30: 403–410.
- Maurea S, Klain M, Caracò C, Ziviello M, Salvatore M. Doagnostic accuracy of radionuclide imaging using iodine-131 nor-cholesterol or MIBG in patients with hypersecreting or non-hypersecreting adrenal tumors. Nucl Med Comm 2002; 23: 951–960.
- Lenders JWM, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 366: 665–675.
- Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Phaeochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 1999; 212: 35–41.
- Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS. 6-[18F]Fluorodopamine positron emission tomography (PET) scanning for diagnostic localisation of phaeochromocytoma. Hypertension 2001; 38: 6–8.
- Adams S, Baum R, Rink T, Schumm-Drager PM, Usedel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998; 25: 79–83.
- Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Itoh K, Imamura M, Konishi J. Evaluation of pancreatic islet cell tumours by fluorine-18 fluorodeoxyglucose positron emission tomography: comparison with other modalities. Clin Nucl Med 2000; 25: 115–119.
Journal of Endocrinology, Metabolism and Diabetes of South Africa
Volume 12, 2007 - Issue 1